Apr 16 |
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
|
Mar 30 |
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
|
Mar 19 |
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
|
Mar 18 |
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
|
Mar 15 |
Cybin initiates Phase 2 study for psychedelic drug DMT
|
Mar 15 |
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
|
Mar 14 |
Cybin to begin Phase 3 study for psychedelic drug mid-year
|
Mar 14 |
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
|
Mar 13 |
Cybin launches $150M oversubscribed private placement
|
Mar 13 |
Announces Oversubscribed Private Placement of U.S. $150 Million
|